Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway

Oncogene

Volumn 24, Issue 11, 2005, Pages 1904-1913

  Scholz, Christian ^a   Wieder, Thomas ^a   Starck, Lilian ^a   Essmann, Frank ^a   Schulze Osthoff, Klaus ^b   Dörken, Bernd ^a   Daniel, Peter T ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Arsenic trioxide; ATP; Caspase independence; Mitochondria; Necrosis

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BUTHIONINE SULFOXIMINE; CASPASE; CASPASE 2; CASPASE 9; CASPASE INHIBITOR; CYTOCHROME C; CYTOTOXIC AGENT; EPIRUBICIN; GLUTATHIONE SYNTHASE; LACTATE DEHYDROGENASE; PROTEIN BCL XL; BCL2L1 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN; ORGANOARSENIC DERIVATIVE; OXIDE; PROTEIN BCL 2; PROTEIN BCL X;

ARTICLE; CELL DEATH; DNA DAMAGE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; PRIORITY JOURNAL; APOPTOSIS; DRUG EFFECT; FIBROBLAST; KINETICS; METABOLISM; NECROSIS; PHYSIOLOGY; PROMYELOCYTIC LEUKEMIA; TUMOR CELL LINE; ULTRASTRUCTURE;

APOPTOSIS; ARSENICALS; BCL-X PROTEIN; CASPASE 2; CASPASE 9; CASPASES; CELL DEATH; CELL LINE, TUMOR; FIBROBLASTS; HUMANS; KINETICS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MITOCHONDRIA; NECROSIS; OXIDES; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 16244393359     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1208233     Document Type: Article

References (62)

1. Akao Y, Mizoguchi H, Kojima S, Naoe T, Ohishi N and Yagi K. (1998). Br. J. Haematol., 102, 1055-1060.
2. Belka C, Rudner J, Wesselborg S, Stepczynska A, Marini P, Lepple-Wienhues A, Faltin H, Bamberg M, Budach W and Schulze-Osthoff K. (2000). Oncogene, 19, 1181-1190.
3. Belka C, Schmid B, Marini P, Durand E, Rudner J, Faltin H, Bamberg M, Schulze-Osthoff K and Budach W. (2001). Oncogene, 20, 2190-2196.
4. Blagosklonny MV. (2000). Leukemia, 14, 1502-1508.
5. Bosanquet AG, Sturm I, Wieder T, Essmann F, Bosanquet MI, Head DJ, Dörken B and Daniel PT. (2002). Leukemia, 16, 1035-1044.
6. Chen YC, Lin-Shiau SY and Lin JK. (1998). J Cell Physiol., 177, 324-333.
7. Dai J, Weinberg RS, Waxman S and Jing Y. (1999). Blood, 93, 268-277.
8. Daniel PT, Kroidl A, Kopp J, Sturm I, Moldenhauer G, Dörken B and Pezzutto A. (1998). Blood, 92, 4750-4757.
9. Daniel PT, Schulze-Osthoff K, Belka C and Güner D. (2003). Essays Biochem., 39, 73-88.
10. Daniel PT, Wieder T, Sturm I and Schulze-Osthoff K. (2001). Leukemia, 15, 1022-1032.
11. Dhein J, Daniel PT, Trauth BC, Oehm A, Moller P and Krammer PH. (1992). J. Immunol., 149, 3166-3173.
12. Engels IH, Stepczynska A, Stroh C, Lauber K, Berg C, Schwenzer R, Wajant H, Janicke RU, Porter AG, Belka C, Gregor M, Schulze-Osthoff K and Wesselborg S. (2000). Oncogene, 19, 4563-4573.
13. Fernandes RS and Cotter TG. (1994). Biochem. Pharmacol., 48, 675-681.
14. Fiers W, Beyaert R, Declercq W and Vandenabeele P. (1999). Oncogene, 18, 7719-7730.
15. Friedrich K, Wieder T, Von Haefen C, Radetzki S, Janicke R, Schulze-Osthoff K, Dörken B and Daniel PT. (2001). Oncogene, 20, 2749-2760.
16. Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G and Debatin KM. (2001). Oncogene, 20, 1063-1075.
17. Gillissen B, Essmann F, Graupner V, Starck L, Radetzki S, Dörken B, Schulze-Osthoff K and Daniel PT. (2003). EMBO J., 22, 3580-3590.
18. Gottlieb E, Vander Heiden MG and Thompson CB. (2000). Mol. Cell Biol., 20, 5680-5689.
19. Güner D, Sturm I, Hemmati PG, Hermann S, Hauptmann S, Wurm R, Budach V, Dörken B, Lorenz M and Daniel PT. (2003). Int. J. Cancer, 103, 445-454.
20. Hasenjäger A, Gillissen B, Müller A, Normand G, Hemmati PG, Schuler M, Dörken B and Daniel PT. (2004). Oncogene, 23, 4523-4535.
21. Hemmati PG, Gillissen B, von Haefen C, Wendt J, Starck L, Güner D, Dörken B and Daniel PT. (2002). Oncogene, 21, 3149-3161.
22. Hu Y, Benedict MA, Ding L and Nunez G. (1999). EMBO J., 18, 3586-3595.
23. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG and Waxman S. (1999). Blood, 94, 2102-2111.
24. Kitamura K, Minami Y, Yamamoto K, Akao Y, Kiyoi H, Saito H and Naoe T. (2000). Leukemia, 14, 1743-1750.
25. Kroemer G and Reed JC. (2000). Nat. Med., 6, 513-519.
26. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F and Berger R. (1991). Blood, 77, 1080-1086.
27. Larochette N, Decaudin D, Jacotot E, Brenner C, Marzo I, Susin SA, Zamzami N, Xie Z, Reed J and Kroemer G. (1999). Exp. Cell Res., 249, 413-421.
28. Leist M and Jaattela M. (2001). Nat. Rev. Mol. Cell Biol., 2, 589-598.
29. Marsden VS, O'Connor L, O'Reilly LA, Silke J, Metcalf D, Ekert PG, Huang DC, Cecconi F, Kuida K, Tomaselli KJ, Roy S, Nicholson DW, Vaux DL, Bouillet P, Adams JM and Strasser A. (2002). Nature, 419, 634-637.
30. Mrozek A, Petrowsky H, Sturm I, Krauss J, Hermann S, Hauptmann S, Lorenz M and Daniel PT. (2003). Cell Death Differ., 10, 461-467.
31. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang T, Waxman S, Wang ZY and Chen SJ. (1999). Blood, 94, 3315-3324.
32. Norbury CJ and Zhivotovsky B. (2004). Oncogene, 23, 2797-2808.
33. Perkins C, Kim CN, Fang G and Bhalla KN. (2000). Blood, 95, 1014-1022.
34. Peter ME and Krammer PH. (2003). Cell Death Differ., 10, 26-35.
35. Prokop A, Wieder T, Sturm I, Essmann F, Seeger K, Wuchter C, Ludwig W-D, Henze G, Dörken B and Daniel PT. (2000). Leukemia, 14, 1606-1613.
36. Prokop A, Wrasidlo W, Lode H, Herold R, Lang F, Henze G, Dörken B, Wieder T and Daniel PT. (2003). Oncogene, 22, 9107-9120.
37. Radetzki S, Kohne CH, von Haefen C, Gillissen B, Sturm I, Dörken B and Daniel PT. (2002). Oncogene, 21, 227-238.
38. Reers M, Smiley ST, Mottola-Hartshorn C, Chen A, Lin M and Chen LB. (1995). Methods Enzymol., 260, 406-417.
39. Robertson JD, Gogvadze V, Kropotov A, Vakifahmetoglu H, Zhivotovsky B and Orrenius S. (2004). EMBO Rep., 5, 643-648.
40. Rudner J, Lepple-Wienhues A, Budach W, Berschauer J, Friedrich B, Wesselborg S, Schulze-Osthoff K and Belka C. (2001). J. Cell Sci., 114, 4161-4172.
41. Saleh A, Srinivasula SM, Acharya S, Fishel R and Alnemri ES. (1999). J. Biol. Chem., 274, 17941-17945.
42. Schelwies K, Sturm I, Grabowski P, Scherubl H, Schindler I, Hermann S, Stein H, Buhr HJ, Riecken EO, Zeitz M, Dörken B and Daniel PT. (2002). Int. J. Cancer, 99, 589-596.
43. Schmelz K, Wieder T, Tamm I, Müller A, Essmann F, Geilen CC, Schulze-Osthoff K, Dörken B and Daniel PT. (2004). Oncogene, 23, 6743-6759.
44. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z and Wang ZY. (1997). Blood, 89, 3354-3360.
45. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP and Warrell Jr RP. (1998). N. Engl. J. Med., 339, 1341-1348.
46. Sturm I, Petrowsky H, Volz R, Lorenz M, Radetzki S, Hillebrand T, Wolff G, Hauptmann S, Dörken B and Daniel PT. (2001). J. Clin. Oncol., 19, 2272-2281.
47. Troy CM and Shelanski ML. (2003). Cell Death Differ., 10, 101-107.
48. van Loo G, Saelens X, van Gurp M, MacFarlane M, Martin SJ and Vandenabeele P. (2002). Cell Death Differ., 9, 1031-1042.
49. Vander Heiden MG, Chandel NS, Li XX, Schumacker PT, Colombini M and Thompson CB. (2000). Proc. Natl. Acad. Sci. USA, 97, 4666-4671.
50. Vermes I, Haanen C, Steffens-Nakken H and Reutelingsperger C. (1995). J. Immunol. Methods, 184, 39-51.
51. von Haefen C, Wieder T, Essmann F, Schulze-Osthoff K, Dörken B and Daniel PT. (2003). Oncogene, 22, 2236-2247.
52. von Haefen C, Wieder T, Gillissen B, Starck L, Graupner V, Dörken B and Daniel PT. (2002). Oncogene, 21, 4009-4019.
53. Wang TS, Kuo CF, Jan KY and Huang H. (1996). J. Cell Physiol., 169, 256-268.
54. Wang ZG, Rivi R, Delva L, Konig A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell Jr RP and Pandolfi PP. (1998). Blood, 92, 1497-1504.
55. Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, Dörken B and Daniel PT. (2001). Blood, 97, 1378-1387.
56. Wyllie AH, Kerr JF and Currie AR. (1980). Int. Rev. Cytol., 68, 251-306.
57. Yang CH, Kuo ML, Chen JC and Chen YC. (1999). Br. J. Cancer, 81, 796-799.
58. Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S, Takeshita K, Takeshita A and Ohno R. (1998). Leukemia, 12, 1383-1391.
59. Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z and de The H. (1997). Proc. Natl. Acad. Sci. USA, 94, 3978-3983.
60. Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun YP, Dai J, Wang ZY, Chen SJ, Zhang TD, Waxman S, Chen Z and Chen GQ. (1999). J. Natl. Cancer Inst., 91, 772-778.
61. Zong WX, Ditsworth D, Bauer DE, Wang ZQ and Thompson CB. (2004). Genes Dev., 18, 1272-1282.
62. Zou H, Li Y, Liu X and Wang X. (1999). J. Biol. Chem., 274, 11549-11556.